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Abstract Anandamide loses its cannabimimetic activities upon 
hydrolysis to arachidonic acid and ethanolamine. So far the 
anandamide hydrolyzing activity widely distributed in mamma- 
lian organs has been attributed exclusively to an enzyme referred 
to as anandamide amidohydrolase with an optimum pH around 9. 
We found another enzyme hydrolyzing anandamide in a human 
megakaryoblastic cell line (CMK). The enzyme present in the 
12 000 X g pellet of the cell homogenate was solubilized by freeze- 
thaw. The soluhilized enzyme showed an optimal pH around 5, 
and was almost inactive at alkaline pH. The enzyme activity was 
increased by the addition of dithiothreitol. In contrast, anand- 
amide amidohydrolase of RBL-1 cells was mostly insoluble even 
after freeze-thaw, showed an optimal pH at 9, and was not 
affected by dithiothreitol. Furthermore, the enzyme of CMK 
cells was much less sensitive to phenylmethylsulfonyl fluoride and 
methyl arachidonoyl fluorophosphonate potently inhibiting 
anandamide amidohydrolase, and effectively hydrolyzed palmi- 
toylethanolamide, which was a poor substrate for anandamide 
amidohydrolase. Thus, the enzyme of CMK cells is distinguish- 
able from anandamide amidohydrolase. 
© 1999 Federation of European Biochemical Societies. 
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1. Introduction 
Anandamide (arachidonoylethanolamide) was discovered as 
an endogenous ligand for cannabinoid receptors [1], and re- 
ported to show a variety of cannabimimetic activities [2M]. 
The activities are lost when anandamide is hydrolyzed to 
arachidonic acid and ethanolamine [5]. The enzyme hydrolyz- 
ing anandamide has been referred to as N-acylethanolamine 
amidohydrolase [6], anandamide amidase [5], anandamide 
amidohydrolase [7,8], or fatty acid amide hydrolase (FAAH)  
[9]. However, these enzymes are now thought to be identical 
[4]. In this article, we will refer to the enzyme as anandamide 
amidohydrolase. Recently cDNAs for this enzyme were 
cloned from the liver of rat, mouse and human [9,10]. 
The anandamide hydrolyzing activities found in various 
mammal ian organs and cell lines have been attr ibuted exclu- 
sively to anandamide amidohydrolase [11,12]. Therefore, spe- 
cific inhibitors for the enzyme are expected to be useful for the 
study on physiological significance of anandamide [13]. 
A l though some differences in the catalytic properties were 
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described between the enzymes of N18TG2 neuronal  cells and 
rat basophil ic leukemia (RBL) cells [14], the presence of iso- 
zymes is still unclarified. 
CMK cell is a human megakaryoblastic cell line established 
from the peripheral blood of an acute megakaryoblastic leu- 
kemia patient with Down syndrome [15,16]. In this study, we 
report an anandamide hydrolyzing enzyme in CMK cells 
which is clearly distinct from anandamide amidohydrolase 
in terms of catalytic properties. 
2. Materials and methods 
2.1. Materials 
[1J4C]arachidonic acid was purchased from Amersham Interna- 
tional (Amersham, UK), [1-14C]palmitic acid from Du Pont NEN 
(Boston, MA, USA), arachidonic and pahnitic acids from Nu-Chek- 
Prep (Elysian, MN, USA), anandamide, palmitoylethanolamide and 
methyl arachidonoyl fluorophosphonate (MAFP) from Cayman 
Chemical Company (Ann Arbor, MI, USA), phenylmethylsulfonyl 
fluoride (PMSF) from Sigma (St. Louis, MO, USA), dithiothreitol 
(DTT) from Wako Pure Chemical Company (Osaka, Japan), protein 
assay dye reagent concentrate from Bio-Rad (Hercules, CA, USA), 
and precoated silica gel 60 F254 glass plates for thin-layer chroma- 
tography (TLC) (20 cm×20 cm, 0.25 mm thickness) from Merck 
(Darmstadt, Germany). [Arachidonoyl-l-14C]anandamide an  [palmi- 
toyl-lJ4C]palmitoylethanolamide were chemically prepared from 
ethanolamine and [1J4C]arachidonic acid or [1J4C]palmitic acid 
[17]. [1J4C]oleamide [18] and 2-[124C]arachidonoyl-sn-glycerol [19] 
were prepared as described previously. Fetal calf serum was purchased 
from PAA (Linz, Austria) and RPMI 1640 and Dulbecco's modified 
Eagle's medium from Gibco BRL (Gaithersburg, MD, USA). CMK 
cells were kindly provided by Dr. Eiji Shimizu of the Third Depart- 
ment of Internal Medicine of our school with a permission of Dr. 
Takeyuki Sato of Chiba University, and RBL-1 cells by Dr. Shuh 
Narumiya of Kyoto University. 
2.2. Cell culture and enzyme preparation 
CMK cells or RBL-1 cells (3 X 106 cells/dish) were plated in a 150 
mm plastic dish with 30 ml of medium. The medium used for CMK 
cells was RPMI 1640 containing 10% fetal calf serum, 2 g/1 of sodium 
bicarbonate and 50 mg/1 of streptomycin sulfate, and that for RBL-I 
cells was Dulbecco's modified Eagle's medium containing 10% fetal 
calf serum, 3.7 g/l of sodium bicarbonate, 100 mg/1 of streptomycin 
sulfate and 105 Units/1 of penicillin G. The dish was placed in a 
humidified 7% CO2/93% air incubator at 37°C. The cells were subcul- 
tured every 3 days. 
CMK or RBL-1 cells were harvested and suspended in phosphate- 
buffered saline at pH 7.4 (PBS) at a density of 1 X 10 7 cells/ml. The 
following procedures were carried out at 4°C. The cells were subjected 
to sonic disruption three times for 15 s. ]'he homogenate of CMK 
cells was centrifuged at 800Xg for 15 rain and at 12000xg for 
30 min, successively. The 12000×g pellet was suspended in PBS 
and subjected to freeze-thaw twice. The sample was centrifuged again 
at 12 000 × g for 30 rain. The resultant supernatant was designated as 
the CMK enzyme and used in the assays of Figs. 14.  In the case of 
RBL-1 cells, the homogenate was freeze-thawed twice, and centrifuged 
at 105 000 x g for 40 rain. The resultant pellet was suspended in PBS, 
and used as the RBL-1 enzyme in the assays of Figs. 14. All the 
samples thus prepared were stored at -80°C until use. Protein con- 
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centration was determined by the method of Bradford [20] with bo- 
vine serum albumin as a standard. 
2.3. Enzyme assay 
The enzyme was incubated with 100 ~tM [I4C]anandamide (10000 
cpm in 5 lal of dimethyl sulfoxide) at 37°C for 30 rain in 100 btl of 50 
mM citrate-sodium phosphate (pH 5.0) containing 3 mM DTT. Ter- 
mination of the reaction, separation of the product by TLC, and 
quantification of the radioactivity were carried out as described pre- 
viously [8]. Assays were performed in triplicate. 
For the enzyme assays using whole cells, the cells (1 × 10 ~') were 
suspended in 0.5 ml of serum-free RPMI 1640 medium, and were 
incubated with 10 gM [HCJanandamide (10000 cpm in 5 btl of etha- 
nol) for different ime periods in a humidified 7% CO2/93% air incu- 
bator at 37°C. The medium was then acidified, and lipids were ex- 
tracted from the medium containing the cells with the combination of 
1 ml of chloroform and 0.5 ml of methanol. The extract was evapo- 
rated, dissolved in diethyl ether and subjected to TLC. 
3. Results 
Human megakaryoblastic cells (CMK) were subjected to 
sonic disruption, and various subcellular fractions were pre- 
pared by sequential centrifugation. Each fraction was incu- 
bated with 14C-labelled anandamide, and the produced 
[14C]arachidonic acid was determined. When the incubation 
was performed at pH 5, approximately 43%, 12% and 3% of 
the total activity of the whole homogenate were recovered in 
the 12000×g pellet (mitochondrial- lysosomal fraction), the 
800 ×g pellet (nuclear fraction) and the 105 000 × g pellet (mi- 
crosomal fraction), respectively. As shown in Table 1, the 
specific activity of the anandamide hydrolysis was the highest 
in the 12000×g pellet followed by the 800×g pellet and the 
105000×g pellet. The 105000×g supernatant (cytosol) did 
not hydrolyze anandamide. The enzyme activity of the 
12000×g pellet was solubilized in a yield of 92% by freeze- 
thaw even in the absence of detergent. The soluble enzyme 
showed a specific activity of 0.84 nmol/min/mg protein which 
was about 8-fold higher than that of the homogenate. Inter- 
estingly, the enzyme activity of each fraction was hardly de- 
tectable at pH 9 (Table 1). 
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Fig. 1. pH-dependence of the anandamide hydrolysis by the CMK 
enzyme and the RBL-I enzyme. The CMK enzyme (solid line, 40 
btg protein) and the RBL-1 enzyme (broken line, 80 ~tg protein) 
were allowed to react with 100 gM [14C]anandamide at the indi- 
cated pH. pH was adjusted with the following buffers (50 mM): cit- 
rate-NaxHPO4 (closed circles), Tris-HC1 (open circles), NaeCO3- 
NaHCO3 (closed triangles). The highest activity was expressed as 
100%; the CMK enzyme (pH 5.0), 0.80 nmol/min/lng protein; 
RBL-I enzyme (pH 9.0), 0.84 nmol/min/mg protein. Mean val- 
ues + S.D. are shown (n = 3). 
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Fig. 2. The inhibitory effect of PMSF and MAFP on the anand- 
amide hydrolysis. The CMK enzyme (closed circles, 40 ~g protein) 
and the RBL-1 enzyme (open circles, 140 gg protein) were allowed 
to react with 100 btM [14C]anandamide at pH 5.0 in the presence of 
the indicated concentrations of PMSF (A) or MAFP (B) dissolved 
in 5 btl of dimethyl sulfoxide. The enzyme was preincubated with 
the inhibitors at 37°C for 5 min before anandamide was added. 
DTT at 3 mM was included in the reaction mixture. The activity in 
the absence of the inhibitors was expressed as 100%; the CMK en- 
zyme, 0.89 (A) or 0.94 (B) nmol/min/mg protein; the RBL-1 en- 
zyme, 0.24 (A) or 0.23 (B) nmol/min/mg protein. Mean values_+ S.D. 
are shown (n = 3). 
The same procedure was applied to rat basophil ic leukemia 
(RBL-1) ceils which were previously demonstrated to express 
anandamide amidohydroIase [12,14]. The specific anandamide 
hydrolyzing activity was the highest in the 12000Xg pellet, 
and the reaction at pH 9 proceeded about 3-fold faster than 
that at pH 5 (Table 1). The enzyme was solubilized in a low 
yield from the 12 000 Xg pellet of RBL-1 cells by freeze-thaw. 
When the anandamide hydrolase activity of the solubilized 
CMK enzyme was examined between pH 3 and 11, the en- 
zyme was active at acidic pH, and the optimal pH was around 
5 (Fig. 13. The activity was hardly detected at alkaline pH. In 
contrast, the RBL-I  enzyme showed the highest activity at pH 
9 under the same assay conditions. 
PMSF [5,8] and MAFP [21,22] were reported to inhibit 
anandamide amidohydrolase. As shown in Fig. 2A, PMSF 
inhibited the RBL-1 enzyme dose-dependently with an IC50 
of about 20 btM, while the CMK enzyme was inhibited with 
an ICs0 of as high as about 3 mM. Similarly, MAFP ,  which 
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Fig. 3. The stimulatory effect of DTT on the anandamide hydroly- 
sis. The CMK enzyme (closed circles, 40 ~tg protein) and the RBL-1 
enzyme (open circles, 140 ~tg protein) were allowed to react with 
100 gM [14C]anandamide at pH 5.0 in the presence of the indicated 
concentrations of DTT. The activity in the absence of DTT was ex- 
pressed as 100%; the CMK enzyme, 0.17 nmol/min/mg protein; the 
RBL-1 enzyme, 0.17 nmol/min/mg protein. Mean values+S.D, are 
shown (n = 3). 
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Fig. 4. Hydrolysis of palmitoylethanolamide by the CMK enzyme 
and the RBL-1 enzyme. The CMK enzyme (A, 15 30 gg protein) 
and the RBL-1 enzyme (B, 150 gg protein) were incubated at pH 
5.0 with the indicated concentrations of [14C]anandamide (closed 
circles) or [14C]palmitoylethanolamide (open circles). Mean val- 
ues + S.D. are shown (n = 3). 
potently inhibited the RBL-1 enzyme (IC50, 3 nM), hardly 
inhibited the CMK enzyme up to 10 gM (Fig. 2B). Further- 
more, the added DTT 6-fold increased the anandamide hydro- 
lyzing activity of the CMK enzyme as the concentration of the 
added DTT was raised up to 10 mM, whereas the RBL-1 
enzyme was not affected by DTT at as high as 10 mM (Fig. 
3). 
We also examined the substrate specificity of the two en- 
zyme preparations. At pH 5 the RBL-1 enzyme hydrolyzed 
palmitoylethanolamide at only one third the rate of the anan- 
damide hydrolysis at 200 gM (Fig. 4B). In contrast, palmi- 
toylethanolamide was 1.5-fold more active than anandamide 
with the CMK enzyme (Fig. 4A). Apparent Km values of the 
CMK enzyme for anandamide and palmitoylethanolamide 
were approximately 40 and 10 gM, respectively. Furthermore, 
the CMK enzyme hydrolyzed oleamide (an endogenous leep 
inducer [18]) and 2-arachidonoylglycerol (another endogenous 
cannabinoid receptor ligand [23,24]), which were reported to 
be substrates for anandamide amidohydrolase [9,19], at 12% 
and 740% of the rate of the anandamide hydrolysis as com- 
pared at 100 gM concentration. 
In order to examine whether or not the anandamide hydro- 
lyzing enzyme actually worked in CMK cells, we incubated 
the whole cells with [L4C]anandamide. Lipids were then ex- 
tracted and separated by TLC. Anandamide decreased time- 
dependently while the radioactivity corresponding to non-po- 
lar lipids and polar lipids increased. After 4 h 85% of anand- 
269 
amide disappeared. About 3% of the total radioactivity was 
detected as free arachidonic acid between 0.5 and 4 h. When 
[J4C]anandamide was incubated in a cell-free medium for 4 h, 
98% of the added anandamide remained unchanged. These 
results suggested uptake and hydrolysis of anandamide in 
CMK cells, followed by incorporation of the generated free 
arachidonic acid to neutral lipids and phospholipids. 
4. Discussion 
Anandamide amidohydrolase has been isolated from brain, 
liver and other mammalian tissues, and its catalytic properties 
were investigated extensively [5 8,11,12,14,25,26]. cDNAs for 
the enzyme were cloned [9,10], and the recombinant enzymes 
were also characterized [9,10,19,27,28]. Thus, the following 
properties were confirmed with native and recombinant en- 
zymes: (1) The enzyme is membrane-bound, and detergents 
are required for its solubilization from the membrane [6,8]. (2) 
The optimal pH is around 9 [6,8,12,14,19,25,26]. Recently, the 
enzyme isolated from human brain was also reported to have 
an optimal pH at 9.0 [29]. (3) The enzyme is inhibited by 
serine protease inhibitors such as PMSF [5,8,19[. (4) MAFP  
is an extremely potent inhibitor for the enzyme [19,21,22]. (5) 
Palmitoylethanolamide, which does not bind to cannabinoid 
receptors [30,31] but shows anti-inflammatory effects [32], is a 
less active substrate than anandamide [7,8,14]. 
We found now an anandamide hydrolyzing activity in hu- 
man megakaryoblastic cells (CMK). The enzyme showed sev- 
eral unique properties different from those of the known 
anandamide amidohydrolase: (1) The enzyme was solubilized 
from the 12000Xg pellet by freeze-thaw in the absence of 
detergent. (2) The optimal pH was around 5. (3) The enzyme 
was much less sensitive to PMSF and MAFP  than anand- 
amide amidohydrolase. (4) The enzyme activity was several- 
fold increased by DTT, while the enzyme of RBL-1 cells was 
not affected by DTT. Earlier it was reported that the ananda- 
mide hydrolyzing activity of neuroblastoma cells was 1.3-fold 
increased by 1 mM DTT [26]. (5) The enzyme of CMK cells 
hydrolyzed palmitoylethanolamide faster than anandamide. 
However, we can not rule out the possibility that the two 
substrates are separately hydrolyzed by different enzymes 
with different specificities contained in our enzyme prepara- 
tion. 
In the present work the enzyme of RBL-1 cells was also 
assayed under the same conditions, and showed properties 
Table 1 
Subcellular distribution of the anandamide hydrolase activity in CMK cells and RBL-1 cells 
Specific anandamide hydrolase activity (nmol/min/mg protein) 
Cell line CMK Cell line RBL-1 
pH 5.0 pH 9.0 pH 5.0 pH 9.0 
Homogenate 0.11 + 0.00 0.01 -+ 0.00 0.13 -+ 0.00 0.29 + 0.00 
800 × g pellet 0.12 + 0.00 0.0 l + 0.00 0.16 + 0.00 0.39 + 0.02 
12 000 × g pellet 0.28 + 0.01 n.d. b 0.40 + 0.00 1.10 + 0.06 
105 000 × g pellet 0.02 + 0.00 n.d. 0.19 + 0.00 0.52 + 0.01 
105 000 × g supernatant n.d. n.d. 0.03 + 0.00 0.04 + 0.01 
Soluble fraction after freeze-thaw  0.84 + 0.06 0.02 + 0.00 0.24 + 0.02 0.19 + 0.02 
Insoluble fraction after freeze-thaw a 0.19 + 0.01 0.01 + 0.00 0.69 + 0.00 2.03 + 0.04 
Each enzyme preparation (15 150 gg protein) was allowed to react with 100 gM [14C]anandamide in 50 
50 mM Tris-HC1 (pH 9.0). The values shown are means + S.D. (n = 3). 
aThe 12 000 ×g pellet was suspended in PBS, freeze-thawed twice, and centrifuged again at 12 000×g for 30 
bn.d., below detection limit. 
mM citrate-Na2HPO4 (pH 5.0) or 
min. 
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typical of anandamide amidohydrolase as described before 
[14]. Thus, our results strongly suggest that the enzyme of 
CMK cells is an enzyme distinct from the known anandamide 
amidohydrolase. Especially we should note that the enzyme is 
less sensitive to PMSF since the compound has been used to 
protect anandamide from the enzymatic inactivation in phar- 
macological and behavioral experiments [33 36]. We used 
only CMK cells as a source of the new enzyme, but further 
studies on the tissue distribution of the enzyme may lead to 
elucidation of its physiological role. Previously it was sug- 
gested that the particulate fraction of rat brain contained a 
non-specific short chain amidohydrolase, which hydrolyzed N- 
palmitoylethanolamide [7]. This brain enzyme may be related 
to our enzyme. 
The localization of the CMK enzyme in the 12 000 × g pellet 
(mitochondrial-lysosomal fr ction) and its optimal pH around 
5 suggest that the enzyme is one of lysosomal hydrolases. 
Lysosomes contain a large number of hydrolases which are 
active around pH 5, and some of them are lipid hydrolyzing 
enzymes uch as acid lipase, phospholipases A, and A:, sphin- 
gomyelinase and ceramidase [37]. Further investigation is now 
being undertaken to find out whether or not the anandamide 
hydrolase activity of CMK cells is attributed to an already 
known lysosomal hydrolase. 
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